Natural Polyphenols



Oliventures is committed to the idea that science matters and our product formulations are guided by research we directly conduct and sponsor, as well as scientific studies done over the last several decades by well-respected institutions, on the role natural ingredients play in supporting the body’s natural response to disease.*

Clinical trials and the results of scientific research on the role of natural ingredients in supporting the body’s natural response to disease should be interpreted by trained healthcare professionals. Laboratory and animal trials do not always predict how a particular ingredient will behave in the human body and not all people respond in the same manner. Human clinical trials can be limited by the number and type of patients involved and the design of the trial itself.

As such, the information presented herein is intended for the review and interpretation of healthcare professionals only.


TrePhenol® is a patented blend of olive polyphenols (principally hydroxytyrosol, tyrosol, and their derivatives) developed and clinically tested by Oliventures.

TrePhenol® is 100% natural (not synthesized or otherwise chemically produced) and is extracted from olives, not olive leaves. It is GRAS, non-GMO, and is tested for chemical and pesticide contamination.

Olive oil polyphenols have been clinically shown to have powerful cardiovascular, cancer, joint health, and immune system benefits.1

In vitro clinical tests showed that TrePhenol®

Inhibited the production of ROS by arterial smooth muscle cells (SMCs), inhibited LDL oxidation and produced greater than 5 fold apoptosis induction over vehicle control in 3 of 8 cancer cell lines tested.




Results as Published in the New England Journal of Medicine

After median follow-up of 4.8 years, the olive oil arm of the trial had 62% lower risk of breast cancer11

Olive oil group: absolute risk reduction of approximately 3 cardiovascular events per 1,000 person years11

49% reduction in risk of stroke11

Reduced incidence of diabetes and metabolic syndrome11


PureVida® Reduced Pain and Inflammation

In a clinical trial conducted in Spain (45 patients), investigators sought to demonstrate that the unique combination of natural ingredients in PureVida® could lower CRP levels in women who had survived breast cancer. The trial also sought to demonstrate that PureVida® could reduce joint pain associated with the intake of aromatase inhibitors, a therapy often prescribed in the treatment of hormone- sensitive breast cancer.a,2-4


PureVida® Trial Designa


a In a prospective, multi-center, pilot study of 45 post-menopausal women (mean age 59 years) with Stage 0-IIIA hormone receptor− positive breast cancer receiving stable doses of adjuvant aromatase inhibitor therapy for 2 to 5 years from their diagnosis, PureVida® significantly reduced CRP (C-reactive protein, a key marker of inflammation) levels (p<0.05). In 45 patients examined for safety, reported adverse events (AEs) included abdominal pain in 1 patient (2.2%), constipation in 5 patients (11.1%), headache in 3 patients (6.7%), and abnormal product taste (fish taste) in 14 patients (31.1%). No patients had to discontinue therapy due to AEs. This study was conducted by Oliventures. There has been substantial separate research into the potential benefits of each of the ingredients in PureVida®. The PureVida® trial has not been peer reviewed and more research is needed before drawing any final conclusions.
Results of the PureVida® Trial

  • 70% of patients had a decrease in CRP and the average decrease in CRP was 35% (p=0.007)a
  • CRP reduction at day 60 was statistically significant (p=0.04), which indicated that the effect could be maintained over timea
  • PureVida® reduced CRP in 70% of the patients studied. The higher the CRP, pre-treatment, the higher the reductiona
  • 40% reduction in the pain severitya
  • Clinical relevant drop in pain in all categories measureda
PureVida Trial Results Chart

This product is not intended to diagnose, treat, cure, or prevent any disease. Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease. Limited clinical evidence indicates that PureVida® may lower elevated CRP levels. CRP is one of several markers of inflammation in the body. Limited clinical evidence indicates that PureVida® may reduce joint pain in women taking aromatase inhibitors. These statements have not been evaluated by the U.S. Food and Drug Administration (FDA).


PureVida® has been Shown to Reduce CRP, a Key Marker of Inflammationa


Breast cancer patients with highest levels of inflammatory blood proteins (CRP) were 2-3 times more likely to die than those with the lower levels (N = 734).5


According to the Cleveland Clinic, the Harvard Women’s Health Study showed that high CRP levels were more predictive of coronary conditions and stroke in women that were high colesterol levels.6

Physicians Health Study

The Physicians’ Health Study found that among healthy adult men, those with a high level of CRP were 3X more likely to have a heart attack than those with low levels of CRP. This was among men who had no previous history of heart disease.7


Brigham and Women’s Hospital CANTOS Study: Reducing inflammation without lowering cholesterol significantly lowers rate of current events. Published in New England Journal of Medicine, Aug. 2017.8


Elevated CRP levels are associated with reduced overall and disease-free survival and with increased risk of death (N = 2,910).9

* Oliventures’ products are not intended to diagnose, treat, cure, or prevent any disease.


CardiOlive 25x
Buy 3 Get 1 Free

Shop Now